Integrated metabolomic and transcriptomic profiling in breast cancer has identified ALDH1A3 as a definitive cancer stem cell (CSC) marker, strongly associated with tumor initiation, therapy resistance, and metastatic potential. Here, ALDH1A3 is linked to breast carcinoma.